CN110720512A - Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl - Google Patents
Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl Download PDFInfo
- Publication number
- CN110720512A CN110720512A CN201911135840.8A CN201911135840A CN110720512A CN 110720512 A CN110720512 A CN 110720512A CN 201911135840 A CN201911135840 A CN 201911135840A CN 110720512 A CN110720512 A CN 110720512A
- Authority
- CN
- China
- Prior art keywords
- ccfm16
- autism
- food
- bifidobacterium bifidum
- polychlorinated biphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010003805 Autism Diseases 0.000 title claims abstract description 64
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 64
- 150000003071 polychlorinated biphenyls Chemical group 0.000 title claims abstract description 44
- 235000013305 food Nutrition 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000000855 fungicidal effect Effects 0.000 title description 2
- 239000000417 fungicide Substances 0.000 title description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 69
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 69
- 239000002068 microbial inoculum Substances 0.000 claims abstract description 26
- 230000006399 behavior Effects 0.000 claims abstract description 12
- 206010042008 Stereotypy Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 230000009467 reduction Effects 0.000 claims abstract description 5
- 206010017577 Gait disturbance Diseases 0.000 claims abstract description 4
- 206010061533 Myotonia Diseases 0.000 claims abstract description 4
- 208000028389 Nerve injury Diseases 0.000 claims abstract description 4
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 4
- 230000008764 nerve damage Effects 0.000 claims abstract description 4
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 5
- 235000021107 fermented food Nutrition 0.000 claims description 4
- BTAGRXWGMYTPBY-UHFFFAOYSA-N 1,2,3-trichloro-4-(2,3,4-trichlorophenyl)benzene Chemical compound ClC1=C(Cl)C(Cl)=CC=C1C1=CC=C(Cl)C(Cl)=C1Cl BTAGRXWGMYTPBY-UHFFFAOYSA-N 0.000 claims description 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 230000003930 cognitive ability Effects 0.000 abstract description 7
- 230000021824 exploration behavior Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 45
- 238000002474 experimental method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000035478 Interatrial communication Diseases 0.000 description 6
- 206010003664 atrial septal defect Diseases 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 230000011273 social behavior Effects 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000003955 neuronal function Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000030363 nerve development Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses application of CCFM16 in preparation of a microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl, bifidobacterium bifidum CCFM16 can improve autonomous behavior and exploration behavior in a strange environment caused by autism, relieve social disorder caused by autism, obviously improve stereotypy behavior caused by autism, improve cognitive ability of new objects caused by autism, improve limb coordination ability reduction caused by nerve injury, improve normal body stretching rate, relieve myotonia and posture gait disorder caused by Parkinson's disease, and effectively adsorb polychlorinated biphenyl.
Description
Technical Field
The invention belongs to the technical field of functional microorganisms, and particularly relates to application of CCFM16 in preparation of a microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl.
Background
Autism (Autism), also known as Autism, is recognized as a widespread neurodevelopmental disorder frequently occurring in infants, mainly manifested as social interaction disorder, communication (speech and non-speech) functional impairment and repetitive stereotypy, often accompanied with various clinical symptoms such as intellectual disturbance, epilepsy or hyperactivity, and generally occurring before the age of 3 years. According to the latest data published by the united states center for disease prevention and control (CDC), the prevalence of ASD was 1:59 in 2018, which increased by 15% over 1:68 in 2016, with the prevalence of males being 4-5 times greater than that of females.
ASD is a nerve development disease with high heterogeneity, genetic factors are main factors, but only 5% -25% of causes can be explained, and it is widely believed that ASD may be the result of dynamic development of interaction between susceptibility genes and internal and external environmental factors, thereby influencing development disorder in various aspects of individuals. In recent years, researches show that medicaments, virus infection, heavy metal poisoning and the like in pregnancy or perinatal period can increase the ASD risk of offspring. The population survey shows that the probability of the parents taking sodium valproate during pregnancy to breed ASD children is 7 times that of normal people, the risk of autism of children is increased by 3 times due to severe virus infection in the early pregnancy (the first three months), and the risk of autism of severe bacterial infection in the middle pregnancy (three to six months) is increased by 1.42 times. In addition, infants exposed to excessive amounts of neurotoxic insecticide pesticides (polychlorinated biphenyls (PCBs), organophosphates, etc.) have poor facial recognition ability, difficulty in concentrating attention, and reduced comprehensive intelligence compared to normal infants.
The exact pathophysiological basis for ASD is unclear and there is evidence to support that its major cause is a disorder of the neuroinflammatory system. The number of active microglia in the brain of an autistic patient is 2 times that of a normal person, and has regional differences. The sustained activity and proliferation of glial cells (astrocytes and microglia), with morphological changes, release of a variety of pro-inflammatory mediators (cytokines and chemokines) to coordinate immune responses and to modulate neuronal function and connectivity, and while such responses may serve neuroprotective effects (i.e., to help repair damaged tissue), long-term disturbances of CNS cytokines can lead to the destruction of neuronal function through their role in cognitive and synaptic regulation, including IL-6 and TNF- α, among others.
Polychlorinated biphenyl, also known as chlorinated biphenyl, is a synthetic organic compound, and is a chloride formed by substituting chlorine for hydrogen atoms on a biphenyl ring. The wide industrial use of polychlorinated biphenyls has caused a problem of global environmental pollution. PCBs can be absorbed by the body through the skin, respiratory tract and digestive tract of animals, the absorptivity of the digestive tract is very high, and the PCBs poisoning of poultry and human caused by environmental pollution basically occurs after the PCBs are invaded by mouth and absorbed through the digestive tract.
The significance of screening out the probiotics which can regulate the intestinal function and effectively relieve the autism is great. The use of probiotic-related dietary intervention strategies and approaches also opens new approaches and solutions for the relief of autism.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
The present invention has been made in view of the above-mentioned technical drawbacks.
Therefore, as one aspect of the invention, the invention overcomes the defects in the prior art and provides the application of bifidobacterium bifidum CCFM16 in preparing microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl.
In order to solve the technical problems, the invention provides the following technical scheme: application of bifidobacterium bifidum CCFM16 in preparing microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl, wherein: the bifidobacterium bifidum CCFM16 can be used for preparing microbial inoculum, food or medicine for tolerating gastrointestinal fluids, relieving autism and adsorbing polychlorinated biphenyl.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the bifidobacterium bifidum CCFM16 can be used for preparing microbial inoculum, food or medicine for improving autonomous behaviors caused by autism in strange environments and exploring behavior disorder.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the bifidobacterium bifidum CCFM16 can be used for preparing microbial inoculum, food or medicine for improving social disorder caused by autism.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the bifidobacterium bifidum CCFM16 can be used for preparing microbial agents, foods or medicines for improving stereotypy caused by autism.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the bifidobacterium bifidum CCFM16 can be used for preparing microbial inoculum, food or medicine for improving cognitive dysfunction caused by autism on new objects.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for improving limb coordination capacity reduction caused by nerve injury.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for relieving myotonia and gait disorder caused by Parkinson's disease.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the polychlorinated biphenyl comprises polychlorinated biphenyl Aroclor1242, Aroclor 1254 and Aroclor 1260.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the food comprises fermented food.
The preferred scheme of the application of the bifidobacterium bifidum CCFM16 in preparing the microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is as follows: the fermented food comprises dairy products, bean products and fruit and vegetable products.
The invention has the beneficial effects that: the bifidobacterium bifidum CCFM16 can improve the autonomous behavior and the exploration behavior in a strange environment caused by autism, relieve the social disorder caused by the autism, obviously improve the stereotypy behavior caused by the autism, improve the cognitive ability of the autism to a new object, improve the reduction of the coordination ability of limbs caused by nerve injury, improve the normal extension rate of a body, relieve the myotonia and the gait disorder of postures caused by the Parkinson disease and effectively adsorb polychlorinated biphenyl.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:
FIG. 1 is the colony morphology of Bifidobacterium bifidum CCFM 16;
FIG. 2 is the effect of Bifidobacterium bifidum CCFM16 on the autonomy of autistic rats;
FIG. 3 is a graph showing the effect of Bifidobacterium bifidum CCFM16 on the normal rate of elongation of the autistic rat body;
FIG. 4 is the effect of Bifidobacterium bifidum CCFM16 on social behavior in autistic rats;
FIG. 5 is the effect of Bifidobacterium bifidum CCFM16 on the repeated stereotypy of autistic rats;
FIG. 6 is the effect of Bifidobacterium bifidum CCFM16 on cognitive ability in autistic rats;
FIG. 7 shows the adsorption capacity of Bifidobacterium bifidum CCFM16 on PCBs.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with examples are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Furthermore, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
Bifidobacterium bifidum CCFM16(Bifidobacterium bifidum) is an open strain which is preserved in China general microbiological culture Collection Center (CCM) in 2017 at 17.1.7.with the address of No. 3 of Xilu No. 1 of Beijing Korean district, the institute of microbiology of China academy of sciences with the preservation number of CGMCC NO: 13632.
bifidobacterium bifidum CCFM16 has the following biological properties:
(1) the characteristics of the thallus are as follows: gram-positive, non-sporulating, immotile bacteria.
(2) Colony characteristics: the anaerobic culture for 36 hours forms obvious colony with the diameter of 0.5-2mm, the front shape is round, the side shape is convex, the edge is neat, the color is milky white, the surface is moist and smooth, and no pigment is generated, see figure 1.
(3) Growth characteristics: the cells were cultured in mMRS medium at 37 ℃ under constant temperature anaerobic conditions for about 24 hours to the end of log.
(4) The compound has better tolerance to simulated gastrointestinal fluid;
(5) the open field autonomous exploration capability of the autism rat can be remarkably improved;
(6) the normal body elongation of the rats with autism can be remarkably improved;
(7) the social disorder of the autistic rat can be obviously improved;
(8) the repeated stereotypy behavior of the rat with the autism can be relieved;
(9) the cognitive ability of the autistic rat on new objects can be relieved;
(10) has good adsorption capacity of PCBs.
Example 1: bifidobacterium bifidum CCFM16 has good tolerance to simulated gastrointestinal fluid
Inoculating the frozen bifidobacterium bifidum CCFM16 in an mMRS culture medium (MRS culture medium + 0.05% cysteine hydrochloride), carrying out anaerobic culture at 37 ℃ for 48h, carrying out subculture for 2-3 times by using the mMRS culture medium, mixing 1mL of the culture medium of the bifidobacterium bifidum CCFM16 with 9.0mL of artificial simulated gastric juice (the mMRS culture medium containing 1% pepsin and having the pH of 2.5), carrying out anaerobic culture at 37 ℃, sampling at 0h, 0.5h, 1h and 2h respectively, carrying out pouring culture by using the magar MRS culture medium, carrying out plate colony counting, measuring the viable count and calculating the survival rate.
The survival rate is the ratio of the logarithmic viable count at the sampling time to the logarithmic viable count at the 0h time in the culture solution, and is expressed by%. Adding 1mL of Bifidobacterium bifidum CCFM16 into 9mL of artificial simulated intestinal fluid (mMRS culture medium containing 0.3% of bovine bile salt, 1% of trypsin and pH 8.0), anaerobically culturing at 37 deg.C, sampling at 0h, 0.5h, 1h and 2h respectively, pouring and culturing with mMRS agar culture medium, counting plate colonies, measuring viable count and calculating survival rate. The survival rate is the ratio of the logarithmic viable count at the sampling time to the logarithmic viable count at the 0h time in the culture solution, and is expressed by%. The results of the experiment are shown in tables 1 and 2. The result shows that the bifidobacterium bifidum CCFM16 has better tolerance to the artificial gastrointestinal fluid.
TABLE 1 tolerance of Bifidobacterium bifidum CCFM16 in simulated gastric juice
TABLE 2 tolerance of Bifidobacterium bifidum CCFM16 in artificially simulated intestinal fluids
Example 2: bifidobacterium bifidum CCFM16 has no toxic and side effects on wistar rats
Suspending Bifidobacterium bifidum CCFM16 in 10% skimmed milk to obtain a suspension with a concentration of 3.0 × 108CFU/mL of bacterial suspension. Taking 6 male wistar autism rats with the weight of about 200g, after adapting to the environment for one week, feeding the bacterial suspension with the concentration once a day for intragastric administration, observing for one week, and recording the death and weight conditions.
The results of these tests are listed in table 3. These results show that the feed concentration was 3.0X 108The CFU/mL bifidobacterium bifidum CCFM16 has no obvious influence on rats, no obvious change in body weight and no death phenomenon. The appearance of the rat has no obvious pathological symptoms.
TABLE 3 weight change and mortality in mice
Note: -: no death of rat
Example 3: bifidobacterium bifidum CCFM16 can significantly improve the self-exploration capability of rats with autism
(1) Breeding of autistic young mouse
The method comprises the following steps of (1) breeding healthy male and female wistar rats in an adaptive environment for 1 week, closing the rats in a female-male ratio of 2:1 at 5 nights, observing vaginal embolus in 8 nights, performing vaginal smear if vaginal embolus is not observed, recording the 1 st day of pregnancy when sperm is observed, breeding the rats in cages after conception, and randomly dividing the rats into a model group and a control group. Administering 600mg/kg of sodium Valproate (VPA) (250 mg/mL solution prepared by normal saline) to the abdominal cavity on the 12.5 th day after pregnancy to serve as a model group; the control group pregnant mice are injected with the same amount of normal saline at the same period, and the young mice are weaned 21 days after birth.
(2) Autistic rat experimental grouping
Divided into a control group, a model group and an intervention group.
(3) Open field experiment of autistic rat
The open field experiment mainly aims to observe the autonomous behavior of the experimental animal in a new and different environment and explore the behavior and the tensity. The height of a rat open field reaction box is 30-40 cm, the bottom side is 100cm, the inner wall is black, a digital camera is arranged 2m above the rat open field reaction box, the visual field of the digital camera can cover the inside of the whole open field, the whole experiment process is recorded, each autism rat is tested for 6 minutes, the occurrence frequency and the duration of certain behaviors (the retention time, the movement speed, the movement distance and the like of the animal in the central area and the marginal area in unit time) of the experimental animal in a novel environment are used for reflecting the autonomous behavior and the exploration behavior of the experimental animal in a strange environment. As shown in fig. 2, compared with the rats in the blank group, the cumulative time of exploration in the central area of the open field of the rats with autism shows that the autonomous exploration ability is reduced in the strange environment, and the administration of the bifidobacterium bifidum CCFM16 can remarkably improve the autonomous exploration ability reduction caused by the autism symptom and can also improve the normal body elongation rate (fig. 3), which indicates that the bifidobacterium bifidum CCFM16 screened by the invention can reduce the occurrence of behavioral disturbance diseases such as parkinson and the like.
Example 4: bifidobacterium bifidum CCFM16 can significantly improve the social ability of autistic rats
The experimental modeling, grouping and processing methods are the same as example 3.
Three-box animal social behavior experiments are the most commonly used experiments to assess autistic social disturbance. The detection mice are all male, the birth time difference is not more than 1d, the body mass difference is less than 15g, and the mice are raised in cages. The detection was performed in a transparent three-chamber box with a size of 60cm x60cm x60 cm. 1d before the experiment, all the detected mice are placed in a detection room to adapt to the environment. In the experiment, 1 mouse to be tested is put into a middle chamber and is firstly adapted for 10 min. Then, a strange rat was placed in the left small chamber and covered with an empty wire cage, and the same rat was placed in the right small chamber and covered with the same wire cage. Opening a channel through which the middle small chamber enters the left small chamber and the right small chamber, recording the behavior of the detected mouse within 10min by shooting, and evaluating the social behavior ability of the animal by calculating the time, the contact times and other indexes of the detected animal approaching a certain steel wire cage through software. The experimental result is shown in fig. 4, the contact time between the autism rat and the strange rat is obviously shorter than that of the rats in the blank group, and the bifidobacterium bifidum CCFM16 screened by the invention can improve the social ability of the autism rat.
Example 5: bifidobacterium bifidum CCFM16 can significantly improve repeated stereotypy of rats with autism
The experimental modeling, grouping and processing methods are the same as example 3.
The marble bead burying experiment is a classic experiment for evaluating repeated stereotypy of autism, and the corn cob packing material with the thickness of 5cm is paved in a rat cage box, and is laid flat, 20 glass beads (the diameter is 15mm) are placed in the rat cage box and are divided into five rows, and each row is divided into 4, and the corn cob packing material is regularly arranged. The mice were placed in a cage for 15min and the number of embedded glass beads was counted (embedded volume greater than 50%). The experimental result is shown in fig. 5, the number of the embedded beads of the autistic rat is obviously higher than that of the rats in the blank group, and the bifidobacterium bifidum CCFM16 screened by the invention can effectively relieve the repeated stereotypy of the autistic rat.
Example 6: bifidobacterium bifidum CCFM16 can significantly improve cognitive ability of autistic rats
The experimental modeling, grouping and processing methods are the same as example 3.
The basic procedure for rat object identification experiments consists of mainly 3 stages: (1) during the adaptation period, rats are sequentially placed in an experimental device without any object, so that the rats can be freely explored to adapt to the experimental environment, and the irritability of animals during the experiment is reduced as much as possible. (2) During the familiarity period, two identical objects (A1 and A2) were placed adjacent to or opposite the floor of the experimental setup, the rats were placed in the experimental setup with the two objects facing away from each other, and 10min later the animals were removed and placed back in the animal cages. After the corresponding time interval, test period experiments were performed. (3) The test session and the familiarity session are performed similarly, except that one of the two identical objects is exchanged for a different object, and the objects in the test session are referred to as the familiar object (A3) and the novelty object (B), respectively, with respect to the two objects in the familiarity session. The cognitive ability of the animal is evaluated by calculating the time and times of the tested animal approaching the familiar object and the novel object through software. The experimental results are shown in fig. 6, the residence time and frequency of the autism rats in the novelty body are obviously lower than those of the blank group and the group fed with CCFM16, and the bifidobacterium bifidum CCFM16 is shown to be capable of relieving the cognitive ability of the autism rats.
Example 7: bifidobacterium bifidum CCFM16 has good adsorption effect on PCBs
3mL (1.0X 10) of a bacterial solution of Bifidobacterium bifidum CCFM16 in late logarithmic growth stage10CFU/mL) at 4 ℃ for 15min at 8000r/min, removing supernatant, washing bacterial sludge with a synthetic liquid culture medium containing no carbon source, further centrifuging, taking bacterial sludge, adding 3mL of a mixture of Aroclor1242/1254/1260(1:1:1), incubating at 37 ℃ for 24h, detecting the residual quantity of PCBs through a liquid phase, and the experimental result shows that the degradation capacities of Bifidobacterium bifidum CCFM16 on Aroclor1242, 1254 and 1260 are respectively 80.1%, 61.6% and 32% (figure 7).
It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.
Claims (10)
1. Application of bifidobacterium bifidum CCFM16 in preparing microbial inoculum, food or medicine for relieving autism and adsorbing polychlorinated biphenyl is characterized in that: the bifidobacterium bifidum CCFM16 can be used for preparing microbial inoculum, food or medicine for tolerating gastrointestinal fluids, relieving autism and adsorbing polychlorinated biphenyl.
2. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 wherein: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for improving autonomous behaviors caused by autism in strange environments and exploring behavior disorder.
3. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for improving social disorder caused by autism.
4. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial agents, foods or medicines for improving stereotypy caused by autism.
5. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for improving cognitive dysfunction caused by autism on new objects.
6. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for improving limb coordination capacity reduction caused by nerve injury.
7. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the bifidobacterium bifidum CCFM16 can also be used for preparing microbial inoculum, food or medicine for relieving myotonia and gait disorder caused by Parkinson's disease.
8. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the polychlorinated biphenyl comprises polychlorinated biphenyl Aroclor1242, Aroclor 1254 and Aroclor 1260.
9. Use of bifidobacterium bifidum CCFM16 in the preparation of bacterial agents, food or drugs for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 1 or 2, wherein: the food comprises fermented food.
10. Use of bifidobacterium bifidum CCFM16 in the preparation of a bacterial agent, food or medicament for alleviating autism and adsorbing polychlorinated biphenyl as claimed in claim 9 wherein: the fermented food comprises dairy products, bean products and fruit and vegetable products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911135840.8A CN110720512B (en) | 2019-11-19 | 2019-11-19 | Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911135840.8A CN110720512B (en) | 2019-11-19 | 2019-11-19 | Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110720512A true CN110720512A (en) | 2020-01-24 |
| CN110720512B CN110720512B (en) | 2022-04-15 |
Family
ID=69224496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911135840.8A Active CN110720512B (en) | 2019-11-19 | 2019-11-19 | Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110720512B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111073828A (en) * | 2019-11-19 | 2020-04-28 | 江南大学 | Bifidobacterium longum subspecies longum and application thereof |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102373227A (en) * | 2010-08-12 | 2012-03-14 | 上海市农业科学院 | Dihydroxybiphenyl dioxygenase gene for preparing engineering strain for degradation of polychlorinated biphenyls |
| US20140134228A1 (en) * | 2011-08-11 | 2014-05-15 | Nutritional Therapeutics, Inc. | Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| CN106361777A (en) * | 2016-11-28 | 2017-02-01 | 青岛东海药业有限公司 | Application of clostridium butyricum in preparation of preparation for preventing or treating autism |
| CN106834187A (en) * | 2017-03-06 | 2017-06-13 | 江南大学 | A kind of bifidobacterium bifidum and application thereof |
| US20170296518A1 (en) * | 2010-05-26 | 2017-10-19 | The United States Of America As Represented By Department Of Veterans Affairs | Method for diagnosing, preventing, and treating neurological diseases |
| CN107586747A (en) * | 2017-10-27 | 2018-01-16 | 裘正荣 | A kind of composite biological agent and its application in pollution by polychlorinated biphenyles soil is repaired |
| CN109055269A (en) * | 2018-08-22 | 2018-12-21 | 江南大学 | Bifidobacterium longum baby's subspecies CCFM687, its fermented food and its application |
| CN109288874A (en) * | 2018-11-22 | 2019-02-01 | 北京格特基因科技有限公司 | The probiotics of autism-spectrum impaired patients symptom can be improved |
| CN109497520A (en) * | 2018-11-15 | 2019-03-22 | 上海奥医生物医药科技有限公司 | A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof |
| CN110331119A (en) * | 2019-08-19 | 2019-10-15 | 江南大学 | Bifidobacterium bifidum CCFM1063 and its application |
| CN110664848A (en) * | 2019-11-19 | 2020-01-10 | 江南大学 | Application of CCFM1025 in preparing food or medicine for relieving autism and adsorbing PCBs |
| CN110693919A (en) * | 2019-11-19 | 2020-01-17 | 江南大学 | Application of bifidobacterium longum subspecies infantis |
| CN111073828A (en) * | 2019-11-19 | 2020-04-28 | 江南大学 | Bifidobacterium longum subspecies longum and application thereof |
| CN111411051A (en) * | 2019-11-19 | 2020-07-14 | 江南大学 | Lactobacillus helveticus and application thereof |
-
2019
- 2019-11-19 CN CN201911135840.8A patent/CN110720512B/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170296518A1 (en) * | 2010-05-26 | 2017-10-19 | The United States Of America As Represented By Department Of Veterans Affairs | Method for diagnosing, preventing, and treating neurological diseases |
| CN102373227A (en) * | 2010-08-12 | 2012-03-14 | 上海市农业科学院 | Dihydroxybiphenyl dioxygenase gene for preparing engineering strain for degradation of polychlorinated biphenyls |
| US20140134228A1 (en) * | 2011-08-11 | 2014-05-15 | Nutritional Therapeutics, Inc. | Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| CN106361777A (en) * | 2016-11-28 | 2017-02-01 | 青岛东海药业有限公司 | Application of clostridium butyricum in preparation of preparation for preventing or treating autism |
| CN106834187A (en) * | 2017-03-06 | 2017-06-13 | 江南大学 | A kind of bifidobacterium bifidum and application thereof |
| CN107586747A (en) * | 2017-10-27 | 2018-01-16 | 裘正荣 | A kind of composite biological agent and its application in pollution by polychlorinated biphenyles soil is repaired |
| CN109055269A (en) * | 2018-08-22 | 2018-12-21 | 江南大学 | Bifidobacterium longum baby's subspecies CCFM687, its fermented food and its application |
| CN109497520A (en) * | 2018-11-15 | 2019-03-22 | 上海奥医生物医药科技有限公司 | A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof |
| CN109288874A (en) * | 2018-11-22 | 2019-02-01 | 北京格特基因科技有限公司 | The probiotics of autism-spectrum impaired patients symptom can be improved |
| CN110331119A (en) * | 2019-08-19 | 2019-10-15 | 江南大学 | Bifidobacterium bifidum CCFM1063 and its application |
| CN110664848A (en) * | 2019-11-19 | 2020-01-10 | 江南大学 | Application of CCFM1025 in preparing food or medicine for relieving autism and adsorbing PCBs |
| CN110693919A (en) * | 2019-11-19 | 2020-01-17 | 江南大学 | Application of bifidobacterium longum subspecies infantis |
| CN111073828A (en) * | 2019-11-19 | 2020-04-28 | 江南大学 | Bifidobacterium longum subspecies longum and application thereof |
| CN111411051A (en) * | 2019-11-19 | 2020-07-14 | 江南大学 | Lactobacillus helveticus and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| MAO CHAI等: "Different Bifidobacterium bifidum strains change the intestinal flora composition of mice via different mechanisms to alleviate loperamideinduced constipation", 《THE ROYAL SOCIETY OF CHEMISTRY》 * |
| MEGAN R. SANCTUARY等: "Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms", 《PLOS ONE》 * |
| ZHIFENG FANG等: "Probiotics modulate the gut microbiota composition and immune responses in patients with atopic dermatitis: a pilot study", 《EUROPEAN JOURNAL OF NUTRITION》 * |
| 曹歆轶等: "儿童孤独症谱系障碍胃肠道细菌学研究的系统综述", 《上海精神医学》 * |
| 段云峰等: "自闭症的病因和治疗方法研究进展 ", 《中国科学:生命科学》 * |
| 王琳琳等: "具粘附特性的动物双歧杆菌对便秘模型小鼠血清中胃肠调节肽水平的影响"", 《中国食品学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111073828A (en) * | 2019-11-19 | 2020-04-28 | 江南大学 | Bifidobacterium longum subspecies longum and application thereof |
| CN111073828B (en) * | 2019-11-19 | 2022-04-15 | 江南大学 | Bifidobacterium longum subspecies longum and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110720512B (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110664848A (en) | Application of CCFM1025 in preparing food or medicine for relieving autism and adsorbing PCBs | |
| CN110693919A (en) | Application of bifidobacterium longum subspecies infantis | |
| CN111073828B (en) | Bifidobacterium longum subspecies longum and application thereof | |
| CN111411051B (en) | Lactobacillus helveticus and application thereof | |
| CN107858302B (en) | Bacillus subtilis 7K and application thereof | |
| CN109234182A (en) | Lactobacillus plantarum ZJUF T34 and its application | |
| CN109161509A (en) | One plant of bacterial strain that can prevent and treat cattle and sheep diarrhoeal diseases | |
| US8728794B2 (en) | Strain conferring anti-disease properties to host and bacterial cell composition | |
| CN108486000A (en) | A kind of Bifidobacterium single bacterium acidified milk preparation method and applications | |
| CN110720512B (en) | Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl | |
| CN111647526B (en) | Lactobacillus plantarum SD-H9, probiotic microbial inoculum thereof and application thereof | |
| CN112852670B (en) | Bifidobacterium infantis DH231 and fermentation product, application and microecological preparation thereof | |
| CN108295096A (en) | Application of the bacterial strain in prevention and treatment mycotic, bacterial vaginitis preparation | |
| CN115287224A (en) | Yak-derived lactobacillus reuteri for improving intestinal microbial development of indigenous animals and application thereof | |
| CN105385640B (en) | Lactococcus garvieae and its application | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| KR101635997B1 (en) | Pediococcus acidilactici 1- 2- Composition for Preventing Improving or Treating of 1-mediated Immune Disease or 2-mediated Immune Disease Comprising Extracts from Pediococcus acidilactici as an Active Ingredients | |
| CN103361290A (en) | Application of composition of bacillus subtilis BS01 and ganoderma lucidum spore powder in improving sleep | |
| CN112852685B (en) | Lactobacillus plantarum SAL and preparation and application thereof | |
| RU2298032C2 (en) | Bacillus subtilis 1719 BACTERIUM STRAIN AS PRODUCER OF ANTAGONISTICALLY ACTIVE BIOMASS IN RELATES TO PATHOGENIC MICROORGANISMS, AS WELL AS PROTEOLYTIC, AMYLOLYTIC, AND LIPOLYTIC ENZYMES | |
| CN114468306B (en) | Application of bacillus coagulans BC99 in preparation of colitis relieving product or immunoregulation product | |
| CN113913334B (en) | Enterococcus faecalis EF-ZA1107-06 and application thereof | |
| CN111904983B (en) | Use of bacillus licheniformis for manufacturing medicine for relieving mental disease | |
| Gily et al. | Analyze Effectiveness Extract of Worm Lumbricus Rubellus and Pheretima Based on Bacteria Salmonella Typhi and Staphylococcus Aureus. Department of Tropical Medicine, Faculty of Medicine, Universitas Prima Indonesia | |
| CN115838650A (en) | Lactobacillus plantarum and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |